Inhibitors for the Vitamin D Receptor-Coregulator Interaction

Area of Science:

• Molecular Endocrinology
• Nuclear Receptor Signaling
• Drug Discovery

Background:

• The vitamin D receptor (VDR) is a nuclear receptor activated by 1,25-dihydroxyvitamin D3.
• VDR mediates gene transcription via interactions with coregulator proteins, acting as coactivators or corepressors.
• Modulating VDR-coregulator interactions is a key strategy for therapeutic intervention.

Purpose of the Study:

• To summarize approaches for developing compounds that modulate VDR-coregulator interactions.
• To review the development of VDR-coregulator inhibitors and antagonists.
• To discuss the biological effects of these VDR modulators.

Main Methods:

• Phage display libraries to identify coregulator peptides.
• Chemical modification of peptides to create direct VDR-coregulator inhibitors.
• Rational drug design and high-throughput screening for small molecule inhibitors.
• Development of VDR antagonists for allosteric inhibition.

Main Results:

• First direct VDR-coregulator inhibitors were developed from modified coregulator peptides.
• Small molecules targeting VDR-coregulator interactions were identified.
• VDR antagonists were shown to allosterically inhibit VDR-coregulator interactions.
• Dual agonist/antagonist effects and biological activities were characterized.

Conclusions:

• Diverse strategies have yielded effective modulators of VDR-coregulator interactions.
• These VDR modulators, including inhibitors and antagonists, show therapeutic potential.
• Further research into VDR-targeted therapies is warranted based on these findings.